Originally published byEU-Startups
Gate2Brain, a Spanish BioTech company developing a therapeutic candidate for aggressive paediatric and adult brain tumours, has announced a €7 million investment – the largest investment raised by the company to date. The investment represent a 30.4% equity stake and strategic partnership with Shilpa Biocare Pvt Ltd, a wholly owned subsidiary of Shilpa Medicare Limited. “Gate2Brain […]
The post Barcelona-based Gate2Brain secures €7 million to advance brain tumour candidate appeared first on EU-Startups.
🌐
More news from European UnionEuropean Union
EUROPE
Related News
EU won't force publishers to grant dead video games an afterlife
1d ago
Tensordyne makes a big bet on log math to beat Nvidia
1d ago
‘None of us will do it alone’: European solidarity takes over VivaTech
1d ago
Why Amazon hates 'human-in-the-loop' AI governance
21h ago
Britain sending Ukraine an extra 30,000 drones – now 150,000 all up
1d ago